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ABSTRACT
Chlamydia trachomatis can ascend from the cervix to the fallopian tubes and survive for long periods
of time without causing symptoms. The immune response to infection clears the extracellular
organisms but leads to development of a persistent intracellular infection. Repeated cycles of pro-
ductive infection and persistence eventually induce tubal occlusion and infertility. Persistently in-
fected cells continue to synthesize fhe chlamydial 60 kD heat shock protein (hsp60). Immunity to
conserved regions of hsp60 may result in autoimmunity to human hsp60. Expression of hsp60 by
the embryo and decidua during early pregnancy may reactivate hsp60-sensitized lymphocytes,
disturb pregnancy-induced immune regulatory mechanisms, and lead to immune rejection of the
embryo. Due to this mechanism women with tubal infertility who are sensitized to the human hsp60
may have a decreased probability of successful outcome after undergoing in vitro fertilization and
embryo transfer. Infect. Dis. Obstet. Gynecol. 5:128-132, 1997. (C) 1997 Wiley-Liss, Inc.
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ue to recent advances in assisted reproduction
technology many conditions previously con-
sidered to eliminate any chance for fertility are now
eminently treatable. In vitro fertilization (IVF) by-
passes the requirement for patent fallopian tubes
and has rapidly become the treatment of choice for
women with occluded or damaged fallopian tubes.
However, it is only beginning to be appreciated
that the cause of the tubal blockage may also nega-
tively influence postfertilization events. In this ar-
ticle, we focus on the major cause of tubal occlu-
sion in the United States and western Europe,
Chlamydia trachomatis infections. We delineate the
unique aspects of intracellular chlamydial persis-
tence, the immune-mediated mechanism respon-
sible for C. trachomatis-induced tubal damage and,
lastly, the negative consequences these immune
events may have for subsequent fertility after IVF
and embryo transfer.
C. TRACHOMATIS PERSISTENCE
C. trachomatis can exist in two distinct morphologi-
cal types. The extracellular elementary body is the
infectious morphotype, while the intracellular re-
ticulate body is the replicating form of the organ-
ism. C. trachomatis can only divide and reproduce
within mammalian cells and is therefore classified
as an obligate intracellular microorganism. This
ability to reside within mammalian cells allows C.
trachomatis to evade detection by the host’s im-
mune system. Furthermore, the organism has de-
veloped mechanisms to persist under adverse con-
ditions. Untreated C. trachomatis infections have
been shown to persist asymptomatically in the fe-
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male genital tract for years, 1,z and this organism has
been isolated from fallopian tubes of infertile
women with tubal obstruction who had no history
of a symptomatic pelvic infection.3
There is also substantial evidence that C. tracho-
marls can persist in vivo in an intracellular form that
cannot be propagated by in vitro culture.4,s C. tra-
chomatis DNA and protein have been identified in
culture-negative fallopian tubes from women with
postinfectious tubal infertility.
6 The mechanism
underlying chlamydial persistence in an uncultur-
able form has been elucidated in in vitro systems;
evidence for a similar mechanism existing in vivo is
still lacking. Exposure of chlamydial-infected cells
to tumor necrosis factor alpha (TNF-00,7 interferon
gamma (IFN-y),8 or some antibioticss leads to de-
velopment of large aberrant reticulate bodies which
are incapable of replication. These forms remain
viable, however, and when the cytokine or antibi-
otic is removed the aberrent forms convert back to
typical reticulate bodies and the chlamydial life
cycle resumes. With each repeated cycle of produc-
tive infection and persistence the tubal epithelium
becomes increasingly damaged due to cell destruc-
tion and the elaboration of pro-inflammatory me-
diators. Eventually, scarring becomes sufficiently
pronounced to occlude the tube. This scheme of
tubal damage is outlined in Table 1.
C. TRACHOMATIS 57 kD HEAT SHOCK
PROTEIN AND IMMUNE PATHOGENESIS
In its persistent, unculturable form, C. trachomatis
synthesizes very little, if any, of its major structural
components. However, one chlamydial protein, of
57 kD, continues to be produced and at a rate even
higher than under favorable growth conditions.9
This protein has been shown to be a member of the
60 kD heat shock protein (hsp60) family1 with
extensive amino acid sequence homology to the
hsp60s of other bacteria and man.1 Hsp60 is a
highly conserved protein that functions in the in-
tracellular transport and assembly of other proteins.
Under conditions of stress or rapid growth its syn-
thesis is greatly enhanced to prevent protein dena-
turation and incorrect folding and, thereby, maxi-
mize the cell’s ability to survive.z
The chlamydial hsp60 is a potent inducer of in-
flammation. In guinea pigs and monkeys previ-
ously sensitized to Chlamydia, introduction of puri-
TABLE I. Proposed mechanism of
C. trachomatis-induced fallopian tube occlusion
Asymptomatic C. trachomatis infection ascends to the fallopian
tubes.
Extracellular chlamydial elementary bodies activate the host’s
immune response, and IFN-y, TNF-, and other
pro-inflammatory cytokines are released.
The extracellular infection is cleared by the immune system.
IFN-y and TNF-c suspend intracellular chlamydial reticulate
body development but do not affect viability. TNF-a and
other inflammatory mediators locally damage the tubal
epithelia.
When the extracellular infection is cleared, IFN-y and TNF-
production ceases and reticulate body development resumes.
The reticulate bodies differentiate into elementary bodies, the
infected cell is lysed, and other epithelial cells are infected.
The elementary bodies again activate the immune response and
the resulting cytokine production induces chlamydial
persistence and further damage to tubal tissue.
Repeated cycles of productive infection and persistence
eventually lead to fallopian tube occlusion.
fled chlamydial hsp60 induced a delayed hypersen-
sitivity response. 13,4 This suggested that an
immune response to hsp60 might be involved in
chlamydial disease pathogenesis. In man, several
investigations have established associations be-
tween immunity to C. trachomatis hsp60 and recur-
rent salpingitis, tubal occlusion, and ectopic preg-
nancy.
s-18 Very recent studies have further dem-
onstrated that the presence of antibody to the
chlamydial hsp60 was a risk factor for subsequent
development of fallopian tube inflammation. 19
The extensive amino acid sequence homology
between the chlamydial and human hsp60 implies
that under certain conditions a C. trachomatis infec-
tion might induce autoimmunity to one’s own
hsp60. Cell-mediated immunity to synthetic pep-
tides corresponding to regions of the chlamydial
hsp60 that were also present in human hsp60 was
not observed in women with a recent chlamydial
cervicitis and only rarely in women with an initial
episode of salpingitis. It was a frequent finding,
however, in women with recurrent chlamydial sal-
pingitis,z This suggested that repeated or chronic
exposure to the chlamydial hsp60 was required for
development of specific immunity to hsp60 epi-
topes shared between C. trachomatis and man. Evi-
dence of humoral immunity to conserved hsp60
epitopes has been obtained for women with C. tra-
chomatis-associated ecopic pregnancyel and infer-
tile women undergoing IVF.ee
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IMMUNITY TO C. TRACHOMATIS, hsp60, AND
PREGNANCY OUTCOME
The relationship between prior immunity to C. tra-
chomatis and pregnancy outcome remains contro-
versial. We,z3 and others,z4 have presented data
consistent with increasing susceptibility to subse-
quent spontaneous abortion after a chlamydial in-
fection. Circulating anti-chlamydial IgG has also
been associated with IVF failuresz3,z,z6 in some
studies but not others,z7 These studies were all
performed prior to the knowledge that immunity to
the chlamydial hsp60 induces pro-inflammatory re-
sponses. A recent review on the possible influence
of immunity to hsp60 and infertility has been pub-
lished,z8
Whether prior immunity to the chlamydial
hsp60 and to hsp60 epitopes also expressed in hu-
man hsp60 affects pregnancy outcome has become
a critically important question since many women
with tubal factor infertility now seek to become
pregnant via IVF. A negative influence of hsp60-
mediated immunity on pregnancy is a realistic pos-
sibility since the embryoz9 and epithelial cells in
the maternal decidua both express hsp60 during
the early stages of pregnancy. In addition, a murine
hybridoma specific for hsp60 was shown to also
react with the surface of human trophoblast,31 sug-
gesting hsp60 expression by these cells.
In a recent study of 198 women undergoing IVF
and embryo transfer, cervical IgA antibodies to the
C. trachomatis hsp60 were identified in 41 (20.7%)
patients.3z The occurrence of this antibody was
strongly correlated with unsuccessful IVF out-
come. Anti-hsp60 IgA was present in 26.3% of
women who did not become pregnant after embryo
transfer, 33.3% of women with only transient bio-
chemical pregnancies, 30% of women with sponta-
neous abortions, and only 7.3% ofwomen with live
births. There was no relation between hsp60 anti-
body status and numbers of oocytes retrieved or
fertilized. In a subsequent analysis of these same
patients utilizing a synthetic peptide to a region of
the chlamydial hsp60 that is also expressed in man
(amino acids 260-271), it was demonstrated that
the presence of IgA antibodies to this peptide also
correlated with IVF failure and was associated with
only biochemical pregnancies after embryo trans-
fer.22
TABLE 2. Proposed mechanism of hsp60
immunity-related pregnancy loss
A persistent chlamydial fallopian tube infection sensitizes the
woman to regions of hsp60 present in both C. trachomatis
and man.
During the pre- and peri-implantation stages of pregnancy, host
hsp60 is expressed by the embryo and maternal decidua.
Host hsp60 expression reactivates lymphocytes previously
sensitized to the chlamydial hsp60.
The activated lymphocytes release pro-inflammatory cytokines
which induce other lymphoid cells to release inflammatory
and cytotoxic mediators.
Immune system activation disturbs immune regulatory
mechanisms necessary to prevent recognition of paternal
antigens expressed by the semi-allogeneic embryo.
Female immune system recognition of paternal antigens induces
rejection of the embryo.
An analysis of cervical IgA antibodies to the hu-
man hsp60 in 91 women seen for an infertility
evaluation who were not in an IVF program re-
vealed that 14.3% were antibody positive. Humoral
immunity to human hsp60 was associated with a
pro-inflammatory immune response at that site.
The presence of this antibody correlated with de-
tection of IFN-/and TNF-o in the cervix,zz
A third study measuring systemic circulating
IgG antibody to human hsp60 in infertile women,
women with a history of recurrent abortions, and
women with primary infertility demonstrated an
association between this antibody and recurrent
abortion. IgG anti-human hsp60 was present in
11% of fertile women, 12% of infertile women, and
37% of recurrent aborters,zz
The relation between serum anti-hsp60 anti-
bodies and recurrent abortion suggests that this an-
tibody may interfere with embryo development. In
an in vitro mouse model the addition of monoclonal
antibody to mammalian hsp60 severely impeded
embryo development. In IVF, embryos are cul-
tured in medium containing maternal serum. Thus,
if the woman is immunized to conserved hsp60
epitopes, this may interfere with the in vitro de-
velopment of her embryos.
A proposed mechanism of hsp60 immunity-
mediated postfertilization pregnancy loss is out-
lined in Table 2. Expression of hsp60 by the em-
bryo and/or maternal cells could reactivate lympho-
cytes previously sensitized to conserved hsp60
epitopes as a result of an asymptomatic C. tracho-
matis infection. This would result in the elabora-
tion of pro-inflammatory cytokines and induction
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of a localized delayed hypersensitivity response.
Interference with immunoregulatory mechanisms
necessary for maintenance of the semi-allogeneic
embryo would then lead to immune rejection of
the embryo. Another possibility is that a persistent,
inapparent, intracellular C. trachomatis infection is
still present in some women and becomes reacti-
vated as a result of pregnancy-induced immune al-
terations. The host’s response to infection would
then facilitate immune rejection.
FUTURE PROSPECTS
The recently recognized negative effects of an
asymptomatic female upper genital tract chlamyd-
ial infection on pregnancy, the capacity to develop
a persistent infection, and the induction ofimmune
sensitization to conserved regions of hsp60 high-
light even more the necessity for comprehensive C.
trachomatis screening of sexually active women. To
preserve fertility, this infection must be detected
and effectively treated prior to establishment of
persistence in the fallopian tubes. Utilization of
DNA amplification technology, such as polymerase
chain reaction (PCR)-based assays, should also be
mandatory since their sensitivity exceeds that of
any other detection method. Recent advances,
such as the demonstration that specimens obtained
from the entrance to the vagina (introitus) were as
sensitive as endocervical specimens for C. tracho-
matis detection if PCR was utilized,34 should
greatly expand the numbers of women who can be
tested for this organism.
Physicians and other health care professionals
must become advocates for state-of-the-art preven-
tative and diagnostic modalities for women and not
capitulate to non-professionals interested more in
finances than the quality of human lives.
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